Observational study on the effectiveness of biological treatments for inflammatory joint diseases
Official title: Long-term Safety and Effectiveness of Disease Modifying Therapies in Inflammatory Arthropathies: a Multicentre, Phase IV, Longitudinal Observational Study
Run by Diakonhjemmet Hospital · NCT01581294 · Data updated 2026-11-12
This study is testing how well biological treatments work for people with inflammatory joint diseases like rheumatoid arthritis and psoriatic arthritis, while also looking at their safety over time.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 15000 (estimated) |
| Sponsor | Diakonhjemmet Hospital Academic / other |
| Locations | 6 sites (Drammen, Buskerud and 5 other locations) |
| Status | Recruiting |
| Started | April 2012 |
| Main results expected | December 2050 |
| Study ends | December 2050 |
| Registry record updated | August 23, 2022 |
| Trial ID | NCT01581294 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 with a diagnosis of inflammatory arthritis who are starting a new treatment with biological DMARDs.
✕Probably not a fit
Patients with psychiatric disorders, substance abuse issues, or those participating in incompatible studies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study, known as NOR-DMARD, aims to evaluate the effectiveness and long-term safety of biological disease modifying anti-rheumatic drugs (DMARDs) in treating inflammatory joint diseases such as rheumatoid arthritis and psoriatic arthritis. It involves structured follow-up visits at baseline and at regular intervals to assess disease activity, health-related quality of life, and joint damage. The study also collects blood samples for biobanking and systematically records serious adverse events, while exploring predictors of treatment efficacy and cost-effectiveness. The data gathered will help improve treatment strategies and patient outcomes in clinical practice.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better management of inflammatory joint diseases for patients.
How similar studies have gone: Previous studies on the effectiveness of biological DMARDs have shown promising results, indicating that this approach is supported by existing evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>18 years * Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, spondyloarthritis, adult juvenile idiopathic arthritis, undifferentiated arthritis, or any other inflammatory arthritis * Clinical indication to start a new treatment with a biological disease modifying anti-rheumatic drug or a kinase inhibitor Exclusion Criteria: * Unwillingness or unability to give written informed consent * Psychiatric or mental disorders, alcohol abuse or other abuse of substances, language barriers or other factors which makes adherence to the study protocol impossible * Participation in blinded RCTs or other studies incompatible with the NOR-DMARD study protocol
Where it's running
-
Lillehammer Hospital for Rheumatic Diseases
Lillehammer, Oppland, Norway Recruiting -
Førde Hospital
Førde, Sogn Og Fjordane, Norway Recruiting -
University Hospital of Northern Norway
Tromsø, Troms, Norway Recruiting -
Diakonhjemmet Hospital
Oslo, Norway Recruiting -
Vestre Viken HF Drammen Hospital
Drammen, Buskerud, Norway Completed -
St. Olavs Hospital
Trondheim, Sør-Trøndelag, Norway Completed
Study contacts
- Principal investigator: Tore K Kvien, MD, PhD — Diakonhjemmet Hospital
- Study coordinator: Eirik K Kristianslund, MD, PhD
- Email: eirik.kristianslund@gmail.com
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving Care for underserved older Black patients with cardiovascular and other chronic conditions
This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.
-
Oxidative stress in autoimmune joint diseases
Researchers will see if oxidative stress and antioxidant markers differ in adults with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.
-
Diagnosing joint diseases using biomarkers from joint fluid and tissue
This observational study tests whether new and traditional biomarkers from synovial fluid, blood, or joint tissue can help diagnose inflammatory and non-inflammatory joint diseases earlier and more accurately.
-
Tornier Perform Reversed MonoPost Shoulder Implant: Patient Follow-Up in Real World Care
This study tests how well the Tornier Perform Reversed MonoPost shoulder implant works in adults with shoulder problems over two years by following patients after surgery at multiple centers.
-
Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease
This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.
-
Intestinal ultrasound-guided management for inflammatory bowel disease
This study tests if adding point-of-care intestinal ultrasound at every visit changes treatment decisions for adults with Crohn’s disease or ulcerative colitis undergoing disease assessment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.